Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amino Acid PET for Brain Tumors
NCT06667726Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Mar 2026
- Primary completion
- May 2028
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Fluorodopa F 18 in brain tumor, sponsored by Mayo Clinic. Primary endpoint: Impact of 18F-DOPA PET/CT on clinical management at 64 days. Started Mar 2026; status: recruiting.
02
Drugs
Fluorodopa F 18
03
Conditions
brain tumor
Beyond the preview
Go deeper on NCT06667726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06667726.